Rémi Gressin

Suggest Changes
Learn More
8003 Background: We have shown that first-line HDT leads to an improved EFS and OS over CHOP in adults with aggressive NHL (NEJM 2004) and that adding R to the HDT was feasible and might improve the(More)
BACKGROUND This study explored the efficacy and safety of rituximab as treatment of clinical or molecular residual disease after autologous stem-cell transplantation (ASCT) in follicular lymphoma(More)
BACKGROUND MCL is a well-described clinicobiological entity that presents the worst prognosis of the small-cell lymphomas. No treatment is known as the reference treatment. On the basis, first, of(More)